Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
This study evaluated the effectiveness of the anti–COVID-19 vaccine in a long-term chronic hemodialysis population by measuring vaccine-induced antibody levels, and assessing the incidence of infection, hospitalization, intensive care admission, or death due to SARS-CoV-2 infection at 6 and 9 months following vaccination.
A total of 168 patients from the Centro Nacional de Salud Renal (CNSR) of EsSalud who had received the COVID-19 vaccine were included. Antibody levels were measured in March 2022 and June 2022. Serum samples were collected prior to the dialysis session, during the second session of the week, to determine vaccine antibody titers at six and nine months after the second vaccine dose. Clinical data were obtained from the electronic medical records of patients with ESRD on hemodialysis at the CNSR of EsSalud. Post-vaccination COVID-19 infection was identified, and data were collected on hospitalization, intensive care unit (ICU) admission, and mortality.
The final study population comprised 159 patients, with a mean age of 54 ± 14 years. The most common etiologies of chronic kidney disease were hypertension and diabetes (48%). Antibody levels, expressed in BAU/mL, declined between the first and second sampling periods, with a median of 8,500 BAU/mL at the first measurement and 5,495 BAU/mL at the second. Fifteen patients (9.5%) developed mild COVID-19 infection after vaccination; none required hospitalization or ICU admission, and there were no deaths due to COVID-19. The analysis of post-vaccination infection probability by antibody level (BAU/mL) showed that infection risk persisted up to 10,000 BAU/mL, with no significant reduction beyond this threshold.
Antibody levels showed a non-significant decline between the third and sixth months of follow-up, with median titers of 8,500 BAU/mL and 5,495 BAU/mL, respectively. None of the patients who developed COVID-19 required hospitalization or intensive care.
